Lisata Therapeutics, Inc. and Kuva Labs Inc. entered into an amendment to their binding term sheet on February 27, 2026. The amendment extends the expiration date of the term sheet from February 28, 2026, to March 7, 2026. The original binding term sheet, dated January 20, 2026, outlined a negotiated acquisition of Lisata by Kuva. The acquisition plan involves Kuva commencing a tender offer to purchase all outstanding shares of Lisata's common stock on a fully-diluted basis. Following the tender offer, Kuva intends to complete a short-form merger with Lisata under Delaware law.